

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20221
www.uspio.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/765,555	01/19/2001	Carlos F. Barbas III	278012001420	1190
25225 7	7590 09/27/2002			
MORRISON & FOERSTER LLP 3811 VALLEY CENTRE DRIVE SUITE 500		EXAMINER		
			KUBELIK,	KUBELIK, ANNE R
SAN DIEGO,	CA 92130-2332		ART UNIT	PAPER NUMBER
			1638	10
			DATE MAILED: 09/27/2002	1/

Please find below and/or attached an Office communication concerning this application or proceeding.

Page 2

Application/Control Number: 09/765,555

Art Unit: 1638

1. The reply filed 11 October, 2001, is not fully responsive to the Office communication mailed 14 August, 2001, for the reason(s) set forth below and on the attached Notice To Comply With The Sequence Rules or CRF Diskette Problem Report: The Paper Copy of the Sequence Listing was not included with the response.

2. Additionally, the amendment filed 11 October, 2001, to pg 87 of the specification was not entered because no marked-up copy of the paragraph was sent.

The new rules for making amendments require that amendments to the written description of the specification be made by way of a clean replacement paragraph or section and for amendment to the claims by way of clean replacement claims. See 37 CFR 1.121(b)(1)(i) and (ii), 1.121(b)(2)(i) and (ii), and 1.121(c)(1)(i) (2001). The new amendment practice also requires a marked up version of the replacement paragraph, section or claim showing the changes vis-a-vis the prior paragraph, section or claim (respectively). See 37 CFR 1.121(b)(1)(iii), 1.121(b)(2)(iii), and 1.121(c)(1)(ii) (2001).

- 3. Since the above-mentioned reply appears to be *bona fide*, applicant is given a TIME PERIOD of **ONE** (1) **MONTH** or **THIRTY** (30) **DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).
- 4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne R. Kubelik, whose telephone number is (703) 308-5059. The examiner can normally be reached Monday through Friday, 8:30 am 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson, can be reached at (703) 306-3218. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 872-9306 for regular communications and (703) 872-9307 for After Final communications.

Application/Control Number: 09/765,555

Art Unit: 1638

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the patent analyst, Sonya Williams, at (703) 305-2272.

Anne R. Kubelik, Ph.D. September 11, 2002

AMY J. NELSON, PH.D SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600

Amy Ner

## Application No. Applicant(s) BARBAS ET AL. 09/765,555 **Notice to Comply** Examiner Art Unit 1638 Anne R. Kubelik NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)). The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s): 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c). 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e). 7. Other: **Applicant Must Provide:** An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

To Purchase Patentin Software......703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY